Get started
Author

Ian Garner

Observed names: Garner, Ian, Ian M. Garner, Ian M. Garner A, Ian Matthew Garner, Ian M. Garner
ORCID: 0000-0002-4513-5094
Observed ORCID: 0000-0002-4513-5094
OpenAlex ID: A5037311694
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer
2020 · Holly Brunton, Giuseppina Caligiuri, et al. · Cell Reports · 119
PDF
Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis
2016 · Iona C. Evans, Josephine L. Barnes, et al. · Clinical Science · 74
PDF
Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2022 · Pavlina Spiliopoulou, Sarah Spear, et al. · Molecular Cancer Therapeutics · 50
PDF
G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer cells
2025 · Jenna Robinson, Gem Flint, et al. · Genome biology · 20
PDF
Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance
2021 · John Gallon, Erick Loomis, et al. · Clinical Epigenetics · 20
PDF
Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?
2022 · Ian Matthew Garner, Robert Brown · Cancers · 15
PDF
Using Chromatin Accessibility to Delineate Therapeutic Subtypes in Pancreatic Cancer Patient-Derived Cell Lines
2020 · Holly Brunton, Ian M. Garner, et al. · STAR Protocols · 10
PDF
Abstract 2066: Modulation of homologous recombination repair pathway gene expression by a dual EZH2 and EHMT2 histone methyltransferase inhibitor and synergy with PARP inhibitors in ovarian cancer
2021 · Ian M. Garner, Zhuyan Su, et al. · Cancer Research · 2
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer
2019 · Holly Brunton, Giuseppina Caligiuri, et al. · SSRN Electronic Journal · 2
Figure 1 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2025 · Pavlina Spiliopoulou, Sarah Spear, et al.
Figure 3 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2025 · Pavlina Spiliopoulou, Sarah Spear, et al.
Figure 4 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2025 · Pavlina Spiliopoulou, Sarah Spear, et al.
Figure 2 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2025 · Pavlina Spiliopoulou, Sarah Spear, et al.
Figure 5 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2025 · Pavlina Spiliopoulou, Sarah Spear, et al.
Figure 6 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2025 · Pavlina Spiliopoulou, Sarah Spear, et al.
cMYC-mediated immune repression is reversed by inhibition of H3K9/H3K27 methylation maintenance
2023 · Isabel Dye, Sarah Laing, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Supplementary Table from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2023 · Pavlina Spiliopoulou, Sarah Spear, et al.
Supplementary Table from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2023 · Pavlina Spiliopoulou, Sarah Spear, et al.
Data from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2023 · Pavlina Spiliopoulou, Sarah Spear, et al.
Supplementary Figure from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2023 · Pavlina Spiliopoulou, Sarah Spear, et al.
Supplementary Table from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2023 · Pavlina Spiliopoulou, Sarah Spear, et al.
Supplementary Data from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2023 · Pavlina Spiliopoulou, Sarah Spear, et al.
Supplementary Data from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2023 · Pavlina Spiliopoulou, Sarah Spear, et al.
Supplementary Figure from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2023 · Pavlina Spiliopoulou, Sarah Spear, et al.
Supplementary Table from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
2023 · Pavlina Spiliopoulou, Sarah Spear, et al.
Works count: 36
Citation count: 312
H-index: 7
I10-index: 7
Year
Topic
Type